Subscribe to RSS
DOI: 10.1055/s-0039-1686842
A new way of treatment of anaplastic thyroid carcinoma
Anaplastic carcinoma of the thyroid gland is a rare tumor with extreme poor prognosis. The average survival time after diagnosis is 6 months. 5-years survival rate is under 10%. Until to now there are only few treatment options known that can stop the growth of the tumor or the occurence of metastases.
Tyrosine kinase inhibitor which primarly inhibits the new growth of blood vessels are used only in the (second line) therapy of differentiated thyroid carcinoma up to now. This therapy is accompanied by many side effects. We report about an succesfull (off label) use of Lenvatinib in the therapy of anaplastic thyroid carcinoma in primarily unfavourable course in 2 female patients. The oral therapy with tyrosine kinase inhibitor resulted in a fast und significant decline of the disease.
Publication History
Publication Date:
23 April 2019 (online)
© 2019. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Georg Thieme Verlag KG
Stuttgart · New York